Premium
Expression and targeting of transcription factor ATF5 in dog gliomas
Author(s) -
York D.,
Sproul C. D.,
Chikere N.,
Dickinson P. J.,
Angelastro J. M.
Publication year - 2018
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/vco.12317
Subject(s) - glioma , activating transcription factor , transcription factor , cell culture , cytoplasm , microbiology and biotechnology , biology , transcription (linguistics) , cancer research , genetics , gene , linguistics , philosophy
Background Activating transcription factor 5 ( ATF5 ) is a transcription factor that is highly expressed in undifferentiated neural progenitor/stem cells as well as a variety of human cancers including gliomas. Aims In this study, we examined the expression and localization of ATF5 protein in canine gliomas, and targeting of ATF5 function in canine glioma cell lines. Materials and Methods Paraffin‐embedded canine brain glioma tissue sections and western blots of tumours and glioma cells were immunoassayed with anti‐ ATF5 antibody. Viability of glioma cells was tested with a synthetic cell‐penetrating ATF5 peptide ( CP ‐d/n ATF5 ) ATF5 antagonist. Results ATF5 protein expression was in the nucleus and cytoplasm and was present in normal adult brain and tumour samples, with significantly higher expression in tumours as shown by western immunoblotting. CP ‐d/n ATF5 was found to decrease cell viability in canine glioma cell lines in vitro in a dose‐dependent manner. Conclusion Similarities in expression of ATF5 in rodent, dog and human tumours, and cross species efficacy of the CP ‐d/n ATF5 peptide support the development of this ATF5 ‐targeting approach as a novel and translational therapy in dog gliomas.